Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

IMPACT-TB: A Phase II Trial Assessing the Capacity of Low Dose Imatinib to Induce Myelopoiesis and Enhance Host Anti-Microbial Immunity Against Tuberculosis. Imatinib Mesylate per Oral As a Clinical Therapeutic for TB

Cynthia R. Giver, PhD, Pamela A Shaw, PhD, Helen Fletcher, PhD, Deepak Kaushal, PhD, Garcia Pamela, Deborah Omoyege, Gregory Bisson, MD, Tawanda Gumbo, MD, Robert Wallis, MD, Edmund K. Waller, PhDMD, Daniel Kalman, PhD

Blood (2019) 134 (Supplement_1): 1050.

https://doi.org/10.1182/blood-2019-130275

Published: 2019

Journal Articles

Allogeneic Stem Cell Transplantation in Patients ≥70 Years Old

Christopher C Walling, BS, Pamela A Shaw, PhD, Noelle V Frey, MD, Saar I Gill, MBBS, PhD, Elizabeth O. Hexner, MD, Alison W Loren, MD MS, Selina Luger, MD, James K Mangan, MD PhD, Mary Ellen Martin, MD, Jacqueline Smith, CRNP, Edward A. Stadtmauer, MD, David L. Porter, MD

Blood (2016) 128 (22): 2309.

https://doi.org/10.1182/blood.V128.22.2309.2309

Published: 2016

Journal Articles

Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2016) 128 (22): 217.

https://doi.org/10.1182/blood.V128.22.217.217

Published: 2016

Journal Articles

Biomarker Profiling Differentiates Sepsis from Cytokine Release Syndrome in Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL)

Simon F. Lacey, PhD, Pamela A Shaw, PhD, David T Teachey, MD, Scott L. Weiss, MD, Fang Chen, PhD, Vanessa E Gonzalez, M.B.A, Noelle Frey, MD MS, David L Porter, MD, Shannon L Maude, MD PhD, Stephan A Grupp, MD PhD, Edward Pequignot, M.S., Carl H June, MD, Jan J. Melenhorst, PhD

Blood (2016) 128 (22): 2812.

https://doi.org/10.1182/blood.V128.22.2812.2812

Published: 2016

Journal Articles

Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019)

Stephan A. Grupp, MD PhD, Shannon L Maude, MD PhD, Pamela A Shaw, PhD, Richard Aplenc, MD PhD, David M. Barrett, MD PhD, Colleen Callahan, MSN, Simon F. Lacey, PhD BS, Bruce L. Levine, PhD, J Joseph Melenhorst, PhD, Laura Motley, RN, Susan R. Rheingold, MD, David T Teachey, MD, Patricia A. Wood, MD PhD, David Porter, MD, Carl H. June, MD

Blood (2015) 126 (23): 681.

https://doi.org/10.1182/blood.V126.23.681.681

Published: 2015

Journal Articles

Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL

Blood (2015) 126 (23): 683.

https://doi.org/10.1182/blood.V126.23.683.683

Published: 2015

Journal Articles

Biomarkers Accurately Predict Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Acute Lymphoblastic Leukemia (ALL)

David T Teachey, MD, Simon F. Lacey, PhD BSc, Pamela A Shaw, PhD, J Joseph Melenhorst, PhD, Noelle V. Frey, MD, Shannon L Maude, MD PhD, David M. Barrett, MD PhD, Richard Aplenc, MD PhD, Fang Chen, PhD, Julie Fitzgerald, MD PhD, Vanessa Gonzalez, M.B.A, Edward Pequignot, PhD, Susan R. Rheingold, MD, Scott Weiss, MD, Jason C. White, DO, Carl H. June, MD, David L. Porter, MD, Stephan A. Grupp, MD PhD

Blood (2015) 126 (23): 1334.

https://doi.org/10.1182/blood.V126.23.1334.1334

Published: 2015

Journal Articles

Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL

Susan R. Rheingold, MD, Lanyi Nora Chen, BS, Shannon L Maude, MD PhD, Richard Aplenc, MD PhD, Christine Barker, BS, David M. Barrett, MD PhD, Colleen Callahan, MSN, Katherine Cebry, Irina Kulikovskaya, PhD, Simon F. Lacey, PhD BS, Bruce L. Levine, PhD, Jan J. Melenhorst, PhD, Pamela A Shaw, PhD, Anna Sparrow, David T Teachey, MD, Mark Duckworth, BS, Carl H. June, MD, Stephan A. Grupp, MD PhD

Blood (2015) 126 (23): 3769.

https://doi.org/10.1182/blood.V126.23.3769.3769

Published: 2015

NARROW

IMPACT-TB: A Phase II Trial Assessing the Capacity of Low Dose Imatinib to Induce Myelopoiesis and Enhance Host Anti-Microbial Immunity Against Tuberculosis. Imatinib Mesylate per Oral As a Clinical Therapeutic for TB

Allogeneic Stem Cell Transplantation in Patients ≥70 Years Old

Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Biomarker Profiling Differentiates Sepsis from Cytokine Release Syndrome in Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL)

Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019)

Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL

Biomarkers Accurately Predict Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Acute Lymphoblastic Leukemia (ALL)

Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only